Risperidone long-acting injection: the first 50 patients

  • Published 2003


AIMS AND METHOD Risperidone long-acting injection (RLAI) is the first atypical antipsychotic drug to be available in a ‘depot’ formulation. The evidence base underpinning its use is small.We sought to evaluate its early use in clinical practice by a naturalistic follow-up study of the first 50 patients to be prescribed RLAI in one National Health… (More)


1 Figure or Table